Focused On-demand Library for Nucleoside diphosphate phosphatase ENTPD5

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.







Alternative names:

CD39 antigen-like 4; ER-UDPase; Ectonucleoside triphosphate diphosphohydrolase 5; Guanosine-diphosphatase ENTPD5; Inosine diphosphate phosphatase ENTPD5; Nucleoside diphosphatase; Uridine-diphosphatase ENTPD5

Alternative UPACC:

O75356; A1L4C5; Q96RX0


Nucleoside diphosphate phosphatase ENTPD5, known by various names such as ER-UDPase and Guanosine-diphosphatase ENTPD5, plays a crucial role in cellular processes. It specializes in hydrolyzing nucleoside diphosphates, favoring GDP, IDP, and UDP over ADP and CDP. This activity is vital in the endoplasmic reticulum for regulating protein reglucosylation, essential for glycoprotein folding and quality control.

Therapeutic significance:

Understanding the role of Nucleoside diphosphate phosphatase ENTPD5 could open doors to potential therapeutic strategies. Its involvement in protein reglucosylation and glycoprotein folding highlights its importance in cellular function and disease prevention.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.